![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Sportoletti Paolo
Publisher: Informa Healthcare
ISSN: 1042-8194
Source: Leukemia and Lymphoma, Vol.54, Iss.8, 2013-08, pp. : 1780-1782
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Alemtuzumab in chronic lymphocytic leukemia
By James Danelle F Kipps Thomas J
Future Oncology, Vol. 3, Iss. 1, 2007-02 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Andritsos Leslie Khoury Hanna
Current Treatment Options in Oncology, Vol. 3, Iss. 3, 2002-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Realgar induces apoptosis in the chronic lymphocytic leukemia cell line MEC1
Molecular Medicine Reports, Vol. 8, Iss. 6, 2013-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
ZGDHu-1 promotes apoptosis of chronic lymphocytic leukemia cells
International Journal of Oncology, Vol. 41, Iss. 2, 2012-01 ,pp. :